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Propylene glycol (PubChem CID: 1030)Therapeutics based on short interfering RNAs (siRNAs), which act by inhibiting the expression of target
transcripts, represent a novel class of potent and highly speciﬁc next-generation treatments for human skin
diseases. Unfortunately, the intrinsic barrier properties of the skin combined with the large size and negative
charge of siRNAs make epidermal delivery of these macromolecules quite challenging. To help evaluate the
in vivo activity of these therapeutics and reﬁne delivery strategies we generated an innovative reporter mouse
model that predominantly expresses ﬁreﬂy luciferase (luc2p) in the paw epidermis — the region of murine
epidermis that most closely models the tissue architecture of human skin. Combining this animal model with
state-of-the-art live animal imaging techniques, we have developed a real-time in vivo analysis work-ﬂow that
has allowed us to compare and contrast the efﬁcacies of a wide range nucleic acid-based gene silencing reagents
in the skin of live animals. While inhibition was achieved with all of the reagents tested, only the commercially
available “self-delivery”modiﬁedAccell-siRNAs (Dharmacon) produced potent and sustained in vivo gene silenc-
ing. Together, these ﬁndings highlight just how informative reliable reporter mouse models can be when
assessing novel therapeutics in vivo. Using this work-ﬂow, we developed a novel clinically-relevant topical
formulation that facilitates non-invasive epidermal delivery of unmodiﬁed and “self-delivery” siRNAs. Remark-
ably, a sustained N40% luc2p inhibition was observed after two 1-hour treatments with Accell-siRNAs in our
topical formulation. Importantly, our ability to successfully deliver siRNA molecules topically brings these
novel RNAi-based therapeutics one-step closer to clinical use.
Crown Copyright © 2014 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Diagnosis, management and/or treatment of human skin conditions
represent a signiﬁcant healthcare burden. In the UK, 20–30% of the
population has been diagnosed with a skin disease, ~15% of all general
practitioner consultations involve a skin condition, and dermatological
prescriptions are second only to those for painkillers [1]. Advances in
molecular genetics and completion of the human genome project
have signiﬁcantly improved many aspects of clinical dermatology. The
identiﬁcation of pathogenic mutations has greatly improved rarepholino antisense oligonucleo-
edicine, Division of Molecular
ndee, Dundee DD1 5EH, UK.
cLean),
SA, Campus EPFL, Quartier de
r B.V. This is an open access article uheritable skin disorder diagnoses [2,3] and the sub-classiﬁcationof com-
mon skin disorders like ichthyosis vulgaris and atopic dermatitis
eczema [4,5]. Despite these advances, relatively little progress has
been made towards developing speciﬁc and effective treatments for
human skin diseases.
Nucleic acid-based therapeutics, including RNA interference (RNAi)
therapies that function via small interfering RNAs (siRNAs), have
emerged as a promising new class of highly speciﬁc, disease-targeted
treatments for a wide range of human diseases [6,7]. The skin is the
most accessible organ in the body, and therefore, represents a strong
candidate for siRNA therapies [8]. Indeed, these therapeutics have
yielded promising preclinical data for a number of skin conditions,
including psoriasis [9], allergic skin disease [10–12], epidermolysis
bullosa simplex [13], epidermolytic palmoplantar keratoderma [14]
and pachyonychia congenita [15,16]. The ﬁrst siRNA to speciﬁcally
target a mutant allele was evaluated by intradermal injection in a
phase 1b trial for pachyonychia congenita [17]. Unfortunately, this
method of delivery cannot be pursued for future pachyonychia
congenita treatments due to the intense pain associated with injection.nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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delivering RNAi compound (sd-rxRNA from RXi Pharmaceuticals,
Westborough, MA) designed to reduce scarring following planned
surgery, was recently completed (RXI-109, http://www.rxipharma.
com). Although these studies have reported encouraging results, the
technical bottleneck of efﬁciently overcoming the skin's barrier
properties in a patient-friendly and clinically-relevant manner has
slowed translation towards clinical use [17].
Pain-free, non-invasive topical application of siRNA formulations
that facilitate siRNA delivery to the disease-relevant layers of the
epidermis would provide the ideal treatment platform for human skin
conditions. Unfortunately, because of the large size (molecular
weight ≈ 13.5 kDa) and negative charge of siRNA molecules, both of
which impede stratum corneum (the outermost barrier of the skin)
and cell membrane penetration, topical delivery strategies have only
been moderately successful [12,18,19]. siRNAs have been delivered
into mouse skin usingminimally invasive techniques such as electropo-
ration [20], iontophoresis [21] and coated steel and dissolvable
microneedles [22,23]. However, these delivery strategies have not yet
progressed to the clinical trial phase. In the event that siRNAs are able
to successfully penetrate the stratum corneum, siRNA-mediated gene
regulation still requires keratinocyte uptake. “Self-delivery” siRNAs,
like commercially available Accell™-siRNA, which carry chemical
modiﬁcations that enhance cellular uptake, have been developed and
effectively inhibit gene expression without the use of transfection
reagents in vitro and in vivo [24–28].
Evaluation and reﬁnement of in vivo delivery approaches have been
hampered by the lack of reliable animal models. Green ﬂuorescent
protein (GFP) reporter mouse models have provided beneﬁcial insights
into epithelial appendage biology and identiﬁed potential drug targets
for the treatment of hair loss, as well as other skin and hair disorders
[29,30]. siRNA potency [31] and delivery using microneedles [23] have
been evaluated in vivo by monitoring ﬂuorescence in a dual reporter
mouse model. Previous studies have, however, demonstrated that
luciferase imaging is more sensitive than ﬂuorescence imaging [32].
We, therefore, developed a unique transgenic reporter mouse model,
where luciferase expression is conﬁned to the epidermis, for validating
new dermatological therapeutics and reﬁning drug delivery to skin.
Here, we used this innovative animal model to compare and contrast
the real-time in vivo efﬁcacies of unmodiﬁed or modiﬁed siRNAs,
morpholino antisense oligonucleotides and in vivo transfection reagents
in live animals. Excitingly, using this real-time live animal imaging
work-ﬂow, we have developed a relatively simple “gene cream” that
facilitates epidermal delivery of both unmodiﬁed and “self-delivery”-
modiﬁed siRNAs.
2. Materials & methods
2.1. Generation of FLG-luc2p bioluminescence reporter mice
A 10 kb human ﬁlaggrin promoter fragment was derived from a
bacterial artiﬁcial chromosome (BAC clone RP1-14N1) via a two-step
recombineering process. A 10.1 kb fragment containing a 5′ XhoI restric-
tion site, ~10 kb upstream of the transcription start site, exon 1 (partial
5′UTR), the ﬁrst 18-bp of intron 1, and a 3′ MluI restriction site was
ampliﬁed from the BAC clone using primers mentioned in Supplemen-
tary Table 1. A second, 483-bp fragment containing a 5′MluI restriction
site, the last 459-bp of intron 1, the start of exon 2 encompassing the
remainder of the 5′UTR and a 3′ HindIII restriction site was ampliﬁed
from the same BAC clone. Fragments were sequence-veriﬁed and
ligated via their MluI sites, generating the 10.6 kb hFLG-10k human
ﬁlaggrin promoter fragment. Finally, the FLG-10k promoter driven
mammalian codon-optimized, protein destabilized ﬁreﬂy luciferase
gene (luc2p) transgene (FLG-10k-luc2p) was generated by cloning
the FLG-10k fragment into pGL4.21 via the XhoI and HindIII restric-
tion sites. Following sequence and expression veriﬁcation, the FLG-10k-luc2p construct was used to generate a single-copy transgenic
C57BL/6J mouse via embryonic stem cell gene targeting into the
murine Rosa26 locus (TaconicArtemis GmbH, Cologne, Germany).
2.2. In vivo live-animal imaging
FLG-luc2p+/− and FLG-luc2p−/− (WT; wild type) mice (6–12 weeks
old) were housed and used for these studies following the husbandry
and experimental guidelines deﬁned by the UK animal welfare act. In
vivo live-animal imaging of FLG-luc2p+/−micewas performed as previ-
ously described [14], using the Xenogen IVIS 200 imaging system
(PerkinElmer, Waltham, MA). Unless otherwise stated, all images
were capturedwith 1 second (s) exposures. The resulting light emission
was quantiﬁed using LivingImage software 3.0 (PerkinElmer). %L/R ra-
tios were calculated by dividing left paw luciferase light emission
(LLE) by right paw LLE. Baseline luciferase bioluminescent activity was
deﬁned for each experimental animal bymonitoring hindpaw luciferase
activity at 24 hour (h) intervals for 5–6 days prior to treatment.
2.3. Tissue collection for qRT-PCR and Western blot analysis
FLG-luc2p+/− (n=10) andWT (n=5)micewere imaged using the
IVIS 200. Fur was shaved prior to imaging abdominal dorsal and ventral
regions. Following imaging, animals were sacriﬁced. Tissues were har-
vested, divided in half, then snap-frozen in liquid nitrogen and stored
at−80 °C.
For total RNA extraction, tissueswere lysed using TissueLyser LT sys-
tem (Qiagen, Crawley, UK) in 700 μl of buffer RLT containing 1% (v/v) β-
mercaptoethanol for 2 minutes (min) at 4 °C at 50 Hz and further
homogenized by passing through a RNeasy-QIAshredder column
(Qiagen). Total RNA was isolated using the RNeasy Mini kit (Qiagen)
according to the manufacturer's instructions and stored at −80 °C.
Total RNA was reverse transcribed using the High Capacity cDNA
Reverse Transcription kit (Life Technologies, Paisley, UK) according to
the manufacturer's instructions and stored at−20 °C.
Whole tissue lysates were prepared by manual grinding tissues in
liquid nitrogen with a mortar and pestle and reconstituted in 100–
150 μl of RIPA buffer [33] containing 1% (v/v) protease inhibitor cocktail
(Sigma-Aldrich, UK). Lysates were incubated for 15 min on ice, cleared
via centrifugation (16,000 ×g) for 20 min at 4 °C and the supernatant
was stored at−80 °C.
2.4. Taqman quantitative real-time PCR (qRT-PCR)
Luc2p mRNA expression levels were analyzed in triplicate by qRT-
PCR using a custom ﬁreﬂy luciferase luc2p TaqMan assay: probe (5′
ACAACCAGCGCCATTC 3′) and primers (forward — 5′ GGCTACGGCCTG
ACAGAA 3′ reverse — 5′ CTGCGCCAGGCTTGTC 3′) in Type-it™ Fast
SNP PCR Master Mix (Qiagen) using a 7900HT Fast Real-Time PCR
System (Life Technologies). 25 ng template cDNA was used for each
reaction and relative abundances were calculated by ΔΔCT method
using GAPDH as the reference gene. Comparative threshold cycle (CT)
values were calculated using SDS 2.2 software (Life Technologies).
2.5. Immunoblotting
5 μg ofwhole tissue lysateswere resolved in 4–12% Bis–Tris denatur-
ing NuPAGE gels (Life Technologies) and transferred to nitrocellulose
membranes. Membranes were cut at the 50 kDa marker, blocked for
1 h at RT in blocking buffer (3% BSA; 1×TBS, 0.5% Tween 20), and incu-
bated with primary antibodies diluted in blocking buffer overnight at
4 °C. The top half of themembrane was probed with a rabbit polyclonal
antibody to ﬁreﬂy luciferase (GTX125849, Genetex, Irvine, USA) diluted
1:1000 and the bottom half was probed with mouse monoclonal
antibody to β-actin (A5441, Sigma-Aldrich, UK) diluted 1:5000.
Membranes were washed, incubated with 1:5000 Alexa Fluor® 680
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Technologies) and imaged using the LI-COR Odyssey (LI-COR,
Cambridge, UK) as previously described [14].2.6. Histology and immunoﬂuorescence
FLG-luc2p+/− and WT hindpaw skin tissues were dissected and
ﬁxed in neutral buffered formalin for 48 h. Surgical surplus adult
human skin samples were acquired via the Tayside Tissue Bank,
Dundee, UK under ethics approval number TR000281. Tissues were
dehydrated, parafﬁn embedded, sectioned (8 μm) and mounted on
superfrost-plus slides (VWR International). For histopathological analy-
ses, sections were deparafﬁnized and hematoxylin/eosin stained
according to standard protocols.
For immunoﬂuoresence staining, 8 μm fresh-frozen hindpaw skin
tissues, mounted on superfrost-plus slides, were used. Sections were
ﬁxed in cold methanol:acetone (1:1), blocked in 10% (v/v) goat
serum/PBS for 15 min at room temperature, and incubated with 1:500
rabbit anti-K1 (ab15580, Abcam, Cambridge, UK), 1:200 rabbit anti-
FLG [34] or 1:2500 rabbit anti-Luc (ab21176, Abcam) primary antibod-
ies diluted in 10% (v/v) goat serum/PBS and incubated overnight at 4 °C.
Sections were washed with 10% (v/v) goat serum/PBS, probed with
1:350 Alexa Fluor® 568 goat anti-rabbit (Life Technologies) or 1:350
Alexa Fluor® 488 goat anti-rabbit (Life Technologies) for 1 h at room
temperature, washed and counterstained with DAPI (1 μg/mL in PBS)
for 3 min. Immunoﬂuorescence was imaged using the Eclipse E600
ﬂuorescent microscope (Nikon, UK). Histology was imaged using an
Axioskop (Zeiss, USA).2.7. siRNA and MO reagents
Standard, de-salted unmodiﬁed or native Luc2p-targeting (siLUC2P-
2; sense 5′-CGACAAGCCUGGCGCAGUATT-3′), non-targeting control
(NCS4; sense 5′-UAGCGACUAAACACAUCAATT-3′) and non-pathway
targeting control (siNPT; sense 5′-GCAAGCTGCTGGGGGGCGATT-3′)
siRNAs were synthesized by Euroﬁns MWG Operon (Ebersberg,
Germany). Self-delivery modiﬁed Accell™-siRNAs were synthesized
by Dharmacon Research (Thermo Fisher Scientiﬁc). Standard control
oligo (5′-CCTCTTACCTCAGTTACAATTTATA-3′) and luc2p-targeting
LUC2P-2 (5′-TCCATGGTGGCTTTACCAACAGTAC-3′) native and self-
delivery modiﬁed (Vivo) morpholino antisense oligonucleotides were
synthesized by Gene Tools (Philomath, OR, USA).2.8. In vitro luciferase assays
Native- and Accell™-modiﬁed siLUC2P-2, NSC4 and siNPT siRNAs
were evaluated in vitro using a stable HaCaT human keratinocyte cell
line expressing luc2p (pK6a-luc2p) (Zhao, 2011 #586). Brieﬂy, 4000
cells/well were plated in 96-well plates in DMEM/10% (v/v) FCS,
incubated for 18 h, transferred to DMEM and incubated for a further
2 h. Native- and Accell™-siRNAs were added at the indicated
concentrations (n= 8/condition), incubated for 24 h, supplemented
with FCS to 2% (v/v) and incubated for an additional 24 h. Cell viabil-
ity was determined by addition of 2.3 mM (ﬁnal) resazurin dye
(Sigma) and incubation at 37 °C for 90 min. Fluorescence/well was
quantiﬁed using a micro-titer plate reader (530 nm excitation/
590 nm emission). Luciferase activity was assayed using the
LUMIstar OPTIMA plate reader (BMG Labtech, Aylesbury, UK) after
adding an equal volume of 2× Luciferin buffer (50 mM Tris/phos-
phate, pH 7.8, 16 mM MgCl2, 2 mM DTT, 2% w/v Triton X-100, 30%
w/v Glycerol, 1 mM ATP, 1% w/v BSA, 8 μM sodium pyrophosphate,
0.2 mg/mL Luciferin) to each well. Three biological replicate experi-
ments were performed.2.9. Intradermal paw injections
7.5 μM nucleic-acid solutions containing native- or Accell™-siRNAs
(siLUC2P-2 or NSC4) or native- or Vivo-MOs (LUC2P-MO or
Control-MO) were prepared in sterile PBS. For in vivo transfection
reagent studies, 1.5 μM native-siRNA solutions were prepared in
sterile PBS. Invivofectamine® 2.0 (Life Technologies) and Injectin
(BioCellChallenge, France) 1.5 μM siRNA solutions were prepared
according to the manufacturer's instructions.
For each treatment group (3–6 animals/group, as indicated), base-
line (i.e. pre-treatment) %L/R luciferase activity ratios were deﬁned
using IVIS 200 for 5 consecutive days. Following imaging, left paws re-
ceived luc2p-targeting siRNAs or MOs and right paws received control
siRNAs or MOs. For each, a total volume of 40 μL was intradermally
injectedwith a 29-gauge needle. For all control animal cohort injections,
40 μL of vehicle controls were injected into both the left and right paws.
Luciferase activity was monitored as described above at 24 hour inter-
vals until %L/R ratio returned to baseline.
2.10. Topical siRNA formulation and in vivo application
Aquaphor®-siRNA mixtures were prepared by manually mixing
37 μg Aquaphor® healing ointment (Eucerin®, USA) with 300 pmol of
native or Accell™-modiﬁed siLUC2P-2, NSC4 or siNPT siRNAs using a
heat-sealed Pasteur pipette. Aquaphor®-PG-siRNA mixtures were
prepared by mixing Aquaphor® healing ointment (29 μg) with PG
(Thermo Fisher Scientiﬁc) to a ﬁnal concentration of 20% (v/w) (8 μL)
and 300 pmol of native or Accell™-modiﬁed siLUC2P-2, NSC4 or siNPT
siRNAs. FLG-luc2p+/− baseline luciferase activity was deﬁned prior to
initial topical formulation application. Following formulation applica-
tion, the animals were kept anesthetized to allow siRNA penetration
(~45 min). Each application was repeated for ﬁve consecutive days
and luciferase activity was measured at 24 hour intervals.
3. Results
3.1. Generation and characterization of FLG-luc2p+/−mouse model
A bioluminescent reporter mouse model was constructed based on
the ubiquitous and exclusive expression of ﬁlaggrin in the keratohyalin
granules of the stratum granulosum [35]. This was done using a human
ﬁlaggrin (FLG) promoter driven ﬁreﬂy luciferase transgene (FLG-10k-
luc2p), which contains a 10.6 kb modiﬁed FLG promoter (~10 kb
upstream of the FLG transcription start site, a fragment of intron 1 and
the 5′UTR) and the mammalian codon-optimized, protein destabilized
luc2p ﬁreﬂy luciferase gene (Fig. 1a). A single-copy FLG-luc2p transgenic
mouse was generated via embryonic stem cell gene targeting into the
Rosa26 locus.
In vivo live-animal imaging, following luciferin administration, was
used to characterize luc2p gene expression patterns in FLG-luc2p+/−
mice and revealed strong, bilaterally symmetric bioluminescent activity
in the forepaws and hindpaws of these animals (Fig. 1b & c). Much
weaker luciferase activity was observed in the tail, ear, snout, perioral
and perianal regions, as well as shaved dorsal and ventral skin (Supple-
mentary Fig. 1a–b). Immunoblot and qRT-PCR analysis of skin tissues
conﬁrmed that luc2p mRNA was most abundant in the hindpaw and
that luciferase protein was only detectable by immunoblot in the
hindpaw (Supplementary Fig. 1c–d). Finally, immunoﬂuorescence
staining demonstrated that both endogenous mouse ﬁlaggrin and
luciferase were appropriately localized within the stratum granulosum
of FLG-luc2p+/− tissues (Fig. 1d).
Histological comparison of fur-covered mouse epidermal, normal
human epidermal and mouse paw epidermal tissues (Supplementary
Fig. 1e), revealed that the paw epidermis of themouse is the one region
of murine epidermis that most closely models the tissue architecture of
human skin. This, together with the strong, bilaterally symmetric,
Fig. 1. FLG-luc2p mouse model. (a) Schematic diagram of the hFLG-10K-luc2p/Rosa26
knockout-replacement strategy used to generate the FLG-luc2pmouse model. The hFLG-
10K-luc2p transgene contains a 10.6 kb human ﬁlaggrin promoter construct fused to the
mammalian codon-optimized ﬁreﬂy luciferase gene luc2p. Single-copy C57BL/6J FLG-
luc2p mice were generated via embryonic stem cell gene targeting into the murine
Rosa26. (b & c) Luciferase expression patterns in FLG-luc2p+/−mice were deﬁned using
in vivo bioluminescent imaging. Signals were strongest in the forepaws and hindpaws, al-
though expressionwas detected in all skin samplesmonitored (see Supplementary Fig. 1).
(d) WT (FLG-luc2p-/-) and FLG-luc2p+/− hindpaw tissues were hematoxylin/eosin (H&E)
stained, or probed with α-keratin 1, α-ﬁlaggrin, or α-ﬁreﬂy luciferase antibodies and
processed for immunoﬂuorescence microscopy. FLG-luc2p reporter gene expression did
not effect epidermal architecture (H&E) or alter endogenous K1 expression. Importantly,
expression of luciferase and mouse ﬁlaggrin in the stratum granulosum conﬁrmed that
the hFLG-10K-luc2p transgene was appropriately expressed in the skin of FLG-luc2p+/−
mice. Scale bar= 50 µm. (e) In vivo imaging of FLG-luc2p+/−mice (n=12) at 24 hour in-
tervals for 5 consecutive days revealed symmetric bioluminescent activity (%L/R
ratio≈ 101± 9) in the right and left paws at each time point. Color bar depicts luciferase
light emission (LLE) intensity (photons/s/cm2/sr) all throughout. %L/R ratios were calcu-
lated throughout as follows: (left LLE/right LLE) × 100.
Fig. 2. Intradermal injection of unmodiﬁed and "self-delivery" siRNAs mediate in vivo in-
hibition of Luc2p activity. (a) FLG-luc2p+/−mouse hindpaws (6 animals/group) were in-
tradermally injected with PBS, native-siRNAs, or self-delivery modiﬁed Accell™-siRNAs
on Day 0 (noted with *). Left paws were treated with siLUC2P-2 (300 pmol) and right
paws with NSC4 (300 pmol). 40 µl PBS was injected into both paws of PBS control
group. Representative images are shown here (see Supplementary Fig. 2, 3 and 4 for full
dataset). (b) Graph depicts the average %L/R ratio for each cohort over the 7-day time-
course and the error bars represent standard deviation of the mean.
358 V. Hegde et al. / Journal of Controlled Release 196 (2014) 355–362epidermal expression of luc2p in the paws of FLG-luc2p+/− mice
(Fig. 1e) suggested that this animal model was well suited for evaluat-
ing dermatological therapeutics in vivo using a split-body experimentalplatform. Prior to initiating such studies, bioluminescence activity was
monitored in the hindpaws of FLG-luc2p+/− animals at 24 hours inter-
vals for 5 consecutive days. While bioluminescence intensity varied
day-to-day, relative left/right luciferase activity was remarkably consis-
tent (Fig. 1e and Supplementary Fig. 1f).
3.2. Real-time monitoring of siRNA potency, efﬁcacy and longevity in vivo
The hindpaws of FLG-luc2p+/−mice (n = 6 animals) were injected
intradermally with native luc2p-targeting (siLUC2P-2; left paw) and
non-targeting control (NSC4; right paw) siRNAs. Control animal cohorts
(n = 6 animals) were injected with sterile PBS. In vivo imaging
comparing the left and right hindpaws revealed a 57% inhibition of
luciferase activity 24 h after native-siLUC2P-2 siRNA treatment (Fig. 2,
Day 1 and Supplementary Figs. 2 and 3, Day 1). Maximum inhibition
(69%) was recorded 48 h post-injection (Day 2), after which luciferase
activity rapidly returned to baseline within another 48 h (Fig. 2, Day
Fig. 4.Morpholino antisense oligonucleotides inhibit luciferase activity in vivo. (a) Paws of
FLG-luc2p+/− mice (3 animals/group) were intradermally injected with PBS, native
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in left/right luciferase activity, each animal treated with native-
siLUC2P-2 siRNA displayed dramatic luciferase activity inhibitions
(Supplementary Figs. 2 and 3; p ≤ 10−6 at Days 1 and 2).
Accell™ “self-delivery” modiﬁed siRNAs (Accell™-siRNA) facilitate
transfection reagent-free in vitro gene silencing in keratinocyte mono-
layers (Supplementary Fig. 4) and organotypic skin models [24]. Here,
we compared the in vivo potency and longevity of Accell™-siRNAs
relative to native-siRNAs in FLG-luc2p+/− mice. Intradermal injection
of Accell™-siLUC2P-2 siRNAs (n = 6 animals) produced more efﬁcient
and sustainable luc2p knockdown in vivo (Fig. 2 and Supplementary
Fig. 5). After only 24 h, luciferase was reduced by 77% (Fig. 2, Day 1).
Moreover, while native-siRNAs produced similar knockdown effects
for the ﬁrst 48 h (up to Day 2), Accell™-siRNAs mediated knockdown
effects were sustained 48 h longer (up to Day 4) and returned to
baseline more slowly compared to native siRNA treatment (Fig. 2b).
3.3. Comparative analysis of commercial in vivo transfection reagents
The ability of the lipid-based in vivo transfection reagents
Invivofectamine® 2.0 or Injectin to enhance native-siRNA silencing
in vivo was evaluated. Preliminary intradermal injection studies
suggested that larger amounts of Invivofectamine® 2.0 were toxic
when administered this way (data not shown). Therefore, the amount
of native-siRNAused for these studieswas reduced to60 pmol/injection
to minimize the amount of transfection reagent injected. The hindpaws
of FLG-luc2p+/− mice (n = 3 animals/group) were intradermally
injected with complexed (Injectin- or Invivofectamine® 2.0) or
uncomplexed native-siLUC2P-2 (left paw) and NSC4 (right paw)
siRNAs. Control animal cohorts were injected with PBS. While injection
of uncomplexed native-siLUC2P-2 produced modest 26% luciferaseFig. 3. Injectin augments native siRNA-mediated luciferase inhibition in vivo. (a)
Hindpaws of FLG-luc2p+/− mice (3 animals/group) were intradermally injected with
PBS, native siRNAs, Invivofectamine® 2.0-complexed native-siRNAs or Injectin-complexed
native-siRNAs on Day 0 (noted with *). Left paws were treated with siLUC2P-2 (60 pmol)
and right pawswith NSC4 (60 pmol). 40 µl PBSwas injected into both paws of PBS control
group. Representative images are shown here (see Supplementary Fig. 6 for full dataset).
(b) Graph depicts the average %L/R ratio for each cohort over the time-course and the
error bars represent standard deviation of the mean.
morpholino antisense oligonucleotides (native-MO), or self-delivery modiﬁed MOs
(Vivo-MO) on Day 0 (noted with *). Left paws were treated with LUC2P-MO (300 pmol)
and right paws with control-MO (300 pmol). 40 µl PBS was injected into both paws of
PBS control group. Representative images are shown here (see Supplementary Fig. 7 for
full dataset). (b) Graph depicts the average %L/R ratio for each treatment group over the
7-day time-course and the error bars represent standard deviation of the mean.inhibition 24 h post-injection (Day 1), coupling the same amount of
native-siRNA with Injectin resulted in a dramatic 75% inhibition (Fig. 3
and Supplementary Fig. 6). Unfortunately, these knockdown
effects were not sustained, and luciferase activities quickly returned to
baseline within 72 h (Day 3). Injection of even small amounts of
Invivofectamine® 2.0 resulted in edema of the paw, possibly masking
the in vivo activity of the siRNA as only 37% luciferase inhibition was
observed (Fig. 3 and Supplementary Fig. 6).
3.4. Testing alternative gene silencing reagents in vivo
To explore the in vivo efﬁcacy of alternative nucleic acid gene
silencing reagents, native morpholino and “self-delivery” modiﬁed
Vivo morpholino antisense oligonucleotides were evaluated in FLG-
luc2p+/− mice (n = 3 animals/group). Hindpaws were injected with
native or Vivo-modiﬁed luc2p-targeting MO (LUC2P-MO; left paw)
and control-MO (right paw),while control animal cohortswere injected
with PBS alone. In vivo imaging revealed that native- and Vivo-MOs
produced similar knockdown effects 24 h post-treatment (Fig. 4, Day
1 and Supplementary Fig. 8). Unfortunately, these effects were short-
lived and luciferase signals returned to baseline within 72 h (Day 3).
3.5. Non-invasive, topical delivery of siRNA into the epidermis
As mentioned above, a painless (albeit non- or minimally-invasive)
delivery system is required for clinical application of siRNA-based
therapies within dermatology. A recent study demonstrated that topical
application of siRNA-based spherical nucleic acid gold nanoparticles
360 V. Hegde et al. / Journal of Controlled Release 196 (2014) 355–362mixed in an over-the-counter dermatological ointment (Aquaphor®)
conferred potent in vivo target inhibition in mouse back skin [19]. This
prompted us to formulate our luc2p-targeting siRNAs in Aquaphor®
and test their delivery into the paw skin of FLG-luc2p+/−mice. For ﬁve
consecutive days, native- or Accell™-siRNAs were mixed with
Aquaphor® healing ointment and applied to the hindpaws of anesthe-
tized mice (n = 3 animals/group) for 45 min/day. Luciferase activity
was monitored via in vivo imaging prior to initial Aquaphor®/siRNAFig. 5. 50% in vivo inhibition of luciferase activity achieved via topical delivery of
Accell™-siRNAs using a novel siRNA-ointment formulation. (a) 40 µg of the
Aquaphor®-PG-siRNA (native or Accell™) was applied to the paws of FLG-luc2p+/−
mice (3/group) for 50 min; treatments were repeated every 24 h for 5 days (Days
0-4; noted with *). Left paws were treated with siLUC2P-2 (300 pmol) and right
paws with NSC4 (300 pmol). Control group received the Aquaphor®-PG without
siRNA on the left paw and no treatment on the right paw. Representative images
are shown here (see Supplementary Fig. 9 for full dataset). (b) Graph depicts the
average %L/R ratio for each treatment group over the 9-day time-course.application (Supplementary Fig. 8, Day 0) and at 24 hour intervals for
6-days thereafter (Supplementary Fig. 8, Days 1–6). Aquaphor® alone
did not alter luciferase activity. Encouragingly, both native- and
Accell™-siLUC2P-2 reduced luciferase activity by 17% and 20%,
respectively, within 48 h of the ﬁrst treatment (Supplementary Fig. 8,
Day 2). This level of inhibition was maintained during treatment and
for 24 h (Day 5) after treatment termination.
Chemical penetration enhancers, like propylene glycol (PG) that
reversibly alter the barrier properties of the stratum corneum and
potentially increase drug solubility [36,37], are often used in dermatol-
ogy to enhance topical drug delivery. Based on this, and the encouraging
results obtained with Aquaphor® alone, we developed a novel
Aquaphor®-based topical formulation containing propylene glycol
(PG) and determined whether enhanced delivery and subsequent
in vivo luc2p knockdown could be achieved. Native- or Accell™-siRNAs
were mixed with an Aquaphor® ointment containing PG (20% w/v)
and applied to the hindpaws of FLG-luc2p+/−mice as described above
(n = 3 animals/group) and luciferase activity was monitored for 9-
days (Fig. 5; Supplementary Fig. 9). Addition of PG failed to signiﬁcantly
enhance native-siLUC2P-2 mediated luciferase inhibition. Remarkably,
however, addition of PG resulted in 37% luc2p knockdown after the
ﬁrst application of Accell™-siLUC2P-2. Accell™-mediated silencing
peaked at 48% onDay 2 48 h after initial application. This level of knock-
down was sustained as treatment continued and for an additional 24 h
(through Day 5) following the ﬁnal treatment (Fig. 5). Luciferase
activity then slowly returned to baseline. Similar results were obtained
with native- or Accell™-siLUC2P-2 and an unrelated non-pathway
targeting native- or Accell™ control siRNA (siNTP; n = 3 animals/
group; data not shown).
4. Discussion
RNAi-based therapeutics show compelling potential for treating
various skin conditions [9–12], speciﬁcally the dominant-negative sub-
set, which includes numerous keratin disorders [2,3,38]. siRNAs that
speciﬁcally target mutant keratin genes have been designed and tested
in vitro and in vivo in animal models [14,15] and a phase 1b clinical trial
[17]. Unfortunately, the pain associated with the intradermal injections
used to deliver these siRNAs was intolerable; thus, alternative delivery
methods (e.g. topical formulations) are needed. Several studies have
described successful topical delivery of siRNAs into the skin [12,18,19],
but the lack of a tractable, real-time in vivo monitoring system has
slowed validation and possible reﬁnement of these delivery approaches.
Reporter plasmid/siRNA co-injection studies have demonstrated the
efﬁcacies of siRNA inhibitors in vivo, but these studies are prone to
high variability and in some cases large animal cohorts were required
to reach statistical signiﬁcance [14–16]. Here, we developed an innova-
tive in vivomethodology for evaluating epidermal nucleic acid delivery
in live animals in real-time. Combining our reporter mousemodel (FLG-
luc2p+/−) with live animal bioluminescence imaging techniques
produces visual, real-time reporter gene activity readouts. Unlike the
methodologies previously reported, this workﬂow allows the user to
instantly deﬁne experimental outcomes and reduces the need for
time-consuming post-treatment validation studies (e.g. qRT-PCR and
Western blotting). Moreover, the ability to monitor gene expression in
the same mouse everyday greatly reduces the number of animals
required for each experiment.
As a proof-of-concept, we used this workﬂow to compare and con-
trast the efﬁcacies of different siRNA chemistries, morpholino antisense
chemistries and in vivo transfection reagents following intradermal
injection.While previous studies have looked at the individual efﬁcacies
of these reagents in vitro and in vivo, thismethodology has allowed us to
perform the ﬁrst comprehensive, multiple time-point study directly
comparing the in vivo knockdown capacities of different post-
transcriptional gene regulation techniques. Our studies revealed
equivalent initial in vivo inhibitions for all siRNA and morpholino
361V. Hegde et al. / Journal of Controlled Release 196 (2014) 355–362chemistries evaluated. We found that Invivofectamine® 2.0 caused se-
vere edema when delivered via intradermal injection. Injectin, on the
other hand, showed no signs of toxicity and required 5-fold less
native-siRNA to achieve similar levels of luciferase inhibition as those
observed with native- or Accell™-siRNAs alone. Nevertheless, the dura-
tion of Accell™-siRNA mediated inhibition was considerably longer
compared to all other molecules. Together, these ﬁndings indicate that
the “self-delivery” and/or backbone stability modiﬁcations [26–28]
present in Accell™-siRNA prolong target knockdown in vivo and identi-
fy this siRNA chemistry as an attractive RNAi-based therapeutic for clin-
ical use within dermatology.
As mentioned above, developing an effective, non-invasive epider-
mal delivery system would represent a key advance towards clinical
acceptance and administration of nucleic acid-based therapeutics.
Several research groups have made great strides towards developing
such delivery methodologies [12,18,19], but the lack of a reliable, real-
time in vivomonitoring system has slowed topical delivery evaluation
and reﬁnement. Using the parameter deﬁned by Zheng et al. [19] as a
baseline, we formulated Aquaphor®-siRNA ointments containing
native- or Accell™-siRNAs and evaluated their efﬁcacy in our FLG-
luc2p+/− mouse model. Within 48 h of application, modest 20% luc2p
knockdown was observed. As some researchers suggest that only a
50% reduction in mutant protein levels may be required to produce
therapeutic effects for some genetic skin disorders [15], we explored
whether the addition of a chemical penetration enhancer, propylene
glycol (PG), would improve in vivo silencing. Remarkably, topical
application of Accell™-siRNAs formulated in this novel Aquaphor®/PG
ointment resulted in a 2-fold increase in luciferase inhibition compared
to Aquaphor® alone. Indeed, ~50% reporter inhibition was achieved,
which suggests that this new topical formulation may be a truly viable
candidate for siRNA-based therapeutics for skin disorders. Importantly,
previous animal model studies have demonstrated that a 1MUT:2WT
in vivo allele expression ratio results in morphologically normal and
functional skin [39]. These ﬁndings encouragingly suggest that the
~50% reduction in target gene expression that we achieved via topical
siRNA delivery may be sufﬁcient to treat human keratinizing skin
disorders.
Linking the expression of luciferase reporter gene to the human
ﬁlaggrin promoter has given this reporter mouse model added value
within the ﬁeld of investigative dermatology. FLG encodes proﬁlaggrin,
a precursor protein that is post-translationally processed into ﬁlaggrin
monomers, which help form the skin barrier and are vital for the health
and appearance of the skin [5,40]. FLG loss-of-function mutations are
predisposing factors for the very common human skin conditions
icthyosis vulgaris and atopic dermatitis (eczema) [41–43]. It has, there-
fore, been suggested that up-regulating FLG expressionmay prove ther-
apeutically beneﬁcial for one, or all, of these conditions. While we have
not demonstrated alternative uses of the FLG-luc2p+/− animal model in
the current study, it represents the ideal in vivo experimental platform
for testing the efﬁcacy of compounds that regulate FLG gene expression.
5. Conclusions
The work presented here describes a unique and reliable reporter
mouse model that is ideally suited for rapid and robust real-time
in vivo evaluation of novel therapeutics within dermatology. We have
developed a work-ﬂow that has allowed us to compare and contrast
the in vivo efﬁcacies of various nucleic acid-based therapeutic in real-
time. Importantly, this real-time monitoring work-ﬂow has allowed
us to develop a novel topical formulation that non-invasively
delivers both uncomplexed native-siRNAs and “self-delivery”modiﬁed
Accell™-siRNAs into the epidermis. Remarkably, the effectiveness of
this relatively simple, clinic-ready topical formulation suggests that
non-invasive therapeutic delivery of siRNA into the skin may not be as
challenging as previous studies have suggested and brings RNAi-based
therapeutics much closer to clinical use.Acknowledgments
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